NASDAQ:ENTO Entero Therapeutics 8/14/2025 Earnings Report $2.48 +0.16 (+6.90%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$2.52 +0.04 (+1.41%) As of 09/10/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Entero Therapeutics EPS ResultsActual EPS-$0.42Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEntero Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEntero Therapeutics Announcement DetailsQuarterDate8/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsEntero Therapeutics' next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Entero Therapeutics Earnings HeadlinesEntero Therapeutics Appoints Jason Sawyer as Interim CEOSeptember 9 at 5:31 PM | tipranks.comEntero Therapeutics files to sell 4.95M shares of common stock for holdersAugust 26, 2025 | msn.comRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors. | Investors Alley (Ad)Entero Therapeutics Inc trading halted, news pendingAugust 16, 2025 | msn.comEntero Therapeutics stock falls after announcing reverse stock splitAugust 14, 2025 | investing.comEntero Therapeutics, Inc. Announces Reverse Stock Split | ENTO Stock NewsAugust 14, 2025 | gurufocus.comSee More Entero Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Entero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entero Therapeutics and other key companies, straight to your email. Email Address About Entero TherapeuticsEntero Therapeutics (NASDAQ:ENTO) (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases. Entero’s pipeline features multiple lead candidates in varying stages of clinical development. By employing proprietary formulation platforms, the company seeks to optimize oral bioavailability and site‐specific release profiles, enabling precise treatment of localized GI pathology. Entero works closely with academic medical centers, clinical research organizations and patient advocacy groups to advance its programs through regulatory milestones, with the goal of delivering novel treatment options for both adult and pediatric patient populations. Founded in 2018 and headquartered in Massachusetts, Entero Therapeutics operates with a network of partners and investigators across the United States. The company maintains a lean organizational structure to support focused development and commercialization activities in the GI space. Through disciplined clinical execution and strategic alliances, Entero aims to become a leading provider of specialized therapies that address significant unmet needs in gastrointestinal health.View Entero Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
